权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Core C: Experimental Models

核心 C：实验模型

基本信息

批准号：
10263186
负责人：
MICHAEL E. BERENS
金额：
$ 25.11万
依托单位：
CLEVELAND CLINIC LERNER COM-CWRU
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-14 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10263186
关键词：
Animal Model Astrocytes Behavior Blood Brain Neoplasms Cells Cellular Indexing of Transcriptomes and Epitopes by Sequencing Characteristics Clinic Clinical Data Collection DNA Data Databases Dominant-Negative Mutation Electroporation Engineering Event Experimental Models FTH1 gene Female Four Core Genotypes Freezing Generations Genes Genetic Genetically Engineered Mouse Genomics Glioblastoma Glioma Goals Gonadal Steroid Hormones Growth Guidelines H ferritin Heterogeneity Human IACUC Implant Individual Informatics Infrastructure Institution Institutional Review Boards Iron Karyotype determination procedure Knock-out Knockout Mice LCN2 gene Label Modeling Mus Neurofibromatosis 1 Organoids Outcome Paraffin Pathology Patients Performance Ploidies Population Pre-Clinical Model Preclinical Testing Quality Control Reporter Research Personnel Resources Secure Services Sex Chromosomes Sex Differences Specimen Standardization TP53 gene Technology Testing Testis Tissue Banks Tissues Treatment outcome Tumor Cell Line Universities University Hospitals Validation Xenograft procedure Y Chromosome autosome base biobank cancer imaging cell transformation clinically relevant cost effective data sharing experimental study human subject human tissue imaging platform in utero in vivo in vivo imaging in vivo two-photon imaging innovation junctional adhesion molecule male model development mouse model neoplastic cell pathology imaging patient derived xenograft model quality assurance radiological imaging response sex sry Genes transcriptome sequencing transcriptomics tumor microenvironment two photon microscopy

项目摘要

PROJECT SUMMARY The Experimental Models Core is responsible for curation, tracking, quality control, and distribution of all glioblastoma (GBM) animal models (patient-derived xenograft (PDX) models, PDX-derived organoids, syngeneic mouse and genetically engineered mice) for experimental studies in all Projects and biospecimens from humans for validation across multiple institutions. The Core will also be responsible for the generation of organoids from these models, for two-photon in vivo imaging of tumors in mice, and for single cell and spatial transcriptomics as technology resources for the P01. A suite of >180 PDX GBM models and >5 syngeneic mouse models with genomic profiling (DNA, RNA sequencing) are available for hypothesis testing by the projects. Human specimens to confirm findings from mouse models will help validate sex differences, albeit the innate heterogeneity across human patients compared to mouse models is a caveat. The core strengthens the projects and the P01 by coordinating the distribution of models for experimental studies in which the sex of the tumor cells are characterized via sex gene-specific PCR and sex chromosome karyotyping. The goals of the Experimental Models Core will be accomplished through the following specific aims: 1) To create, organize, and maintain infrastructure, then deploy syngeneic and genetically engineered mouse glioma models, patient-derived xenograft GBM models, short-term GBM cultures and organoids, providing high-quality, scientifically relevant biospecimens to P01 investigators using standardized collection, quality control, storage/tracking and distribution under approved IACUC guidelines, and 2) To make high-quality, scientifically-relevant clinical biospecimens available to the P01 investigators through continued efforts and innovations in standardized collection, quality control (including centralized neuro pathology review), storage/tracking and distribution under proper human subject (OHRP) regulatory guidelines using secure, readily accessible databases. A decided benefit of the Experimental Models Core is the coordination and visibility of shared use of models across all Projects, with shared quality control, batch (or passage) effects, growth characteristics, genomic profiling, and cross-Project data sharing from the experimental outcomes.

项目总结